While GAL has demonstrated efficacy in inhibiting tumor progression in preclinical models of pancreatic cancer and HCC, the use of TGF-β inhibitors can lead to a range of side effects, including immunosuppression, hepatotoxicity, and cardiotoxicity, which may limit the use of GAL [41]. This evidence concerns the gene GAL and hepatocellular carcinoma.